Calls for papers
-
The FDA’s Pulmonary-Allergy Drug Advisory Committee (PADAC) voted at its May 11, 2023 meeting in support of approval of ARS Pharmaceuticals’ Neffy intranasal epinephrine for the treatment of allergic reactions, including anaphylaxis, the company announced. Committee members voted… Read more . . .
-
SoftOx Solutions has announced a restructuring plan that includes shutting down its own GMP facility, laying off employees, and outsourcing further development of its SoftOx inhalation solution (SIS) to the University of Copenhagen. The company… Read more . . .
-
Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of “a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention… Read more . . .
-
Codagenix announced that it has initiated a Phase 1 study of its CodaVax-RSV live-attenuated intranasal vaccine candidate in children aged 6 months to 5 years, with the study expected to enroll 18 children aged 2… Read more . . .
-
Nanoparticle technology specialist Nanoform Finland has announced the completion of a successful GMP inspection of its API manufacturing facility by the Finnish Medicines Agency (FIMEA). The company said that the agency issued no critical or… Read more . . .
-
Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in “a near term milestone payment” as well as $3 million… Read more . . .
-
According to Optinose, the FDA has accepted the company’s sNDA to expand the use of Xhance fluticasone propionate nasal spray for the treatment of chronic sinusitis in patients without nasal polyps and has set the… Read more . . .
-
Aerami Therapeutics has issued a statement following the death of CEO Lisa Yañez, who was killed in a car accident on May 2, 2023 in Chapel Hill, NC, USA, offering condolences to Yañez’s family and… Read more . . .
-
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According… Read more . . .
-
Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden